Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2022

View Archived Issues

Blockade of HIF-1 leads to ROS overproduction in diabetes

MZE-001 shows promising results in murine and canine models of Pompe disease

S-05014, a novel tyrosinase inhibitor with promising anti-Parkinsonian activity

Discovery of novel peptides as probes for crotamine

Ideaya Biosciences presents POLQ inhibitors

U.S. researchers divulge CDK19 inhibitors

Columbia University discloses CD33/CD45 interaction inhibitors

New IRAK and FLT3 inhibitors described by U.S. investigators

Mirati Therapeutics synthesizes new SOS1 inhibitors

New DNA Damage Response Consortium seeks to advance brain cancer research

Microlyse targets VWF and clears microvascular thrombosis

Code Bio and Takeda collaborate on gene therapies for rare diseases

Sema4 and BioSymetrics partner on drug discovery in cardiovascular, rare and neurological diseases

Phio's INTASYL-based antiviral compounds against SARS-CoV-2 enter in vivo testing

Actinium and AVEO collaborate to develop novel Ac-225 ErbB3-targeted radiotherapy

ALPHA-1062 shown to be neuroprotective in rodent model of traumatic brain injury

JBC-1847 proven effective against Staphylococcus aureus infection

Cantargia reports non-GLP toxicology and pharmacokinetic data on CAN-10

Sorrento's STI-9167 shows neutralizing activity against SARS-CoV-2 Omicron variants

Novel target identified for long QT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...